Bard winds up for next mesh trial; Study: Insulin pumps beat injections for kids;

@FierceMedDev: Covidien yanks syringes over sterility risk. Report | Follow @FierceMedDev

@DamianFierce: Introducing B-a-MedFounder, a new crowdfunding platform for medical devices. ICYM yesterday's popular story | Follow @DamianFierce

@MarkHFierce: Medtronic reported a double-digit increase in net earnings during Q1. Release | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Platinum-based radiotherapy method zaps cancer with nanomeds. More from FierceDrugDelivery | Follow @MichaelGFierce

> Attorneys have picked a jury for C.R. Bard's ($BCR) next vaginal mesh trial, following a $2 million verdict against the company last week. Story

> Insulin pumps proved better at improving glycemic control and reducing hypoglycemia than injections among children with Type 1 diabetes, according to a study. Article

> Respicardia has kicked off enrollment in its pivotal trial of the Remede device, designed to treat sleep apnea. News

> ERBA Diagnostics ($ERB) posted about $7 million in revenue last quarter, a 60% jump over the same period last year, and eked out a net income of $87,333, besting a $358,680 loss in the second quarter of 2012. Results

> Seven months since it kicked in, the medical device tax hasn't proved too much for industry to handle. More

> U.K. diagnostics outfit Biofortuna has raised about $2 million to expand its technology. Report

Biotech News

@FierceBiotech: ICYMI from FierceBiotechIT: Pfizer taps online marketplace for outsourcing research. Story | Follow @FierceBiotech

@JohnCFierce: I wonder if this will reignite some old rumors of a Novartis buyout for MorphoSys. I suspect so. Article | Follow @JohnCFierce

@RyanMFierce: Pfizer's social head touted some of the internal and external feats of the pharma giant. More | Follow @RyanMFierce

> Adimab adds Celgene to high-profile clientele for antibody drug discovery. News

> Regado has to slash IPO price to complete $42M raise. Report

> Eisai suit prods DEA for slow-motion drug classification roadblock. More

> Analyst urges Merck to overhaul its weak $8B R&D operation. Story

Pharma News

@FiercePharma: Popular this morning on our website: Eli Lilly's $15B battle for longer Alimta monopoly hits court today. Story | Follow @FiercePharma

@CarlyHFierce: The gang at FierceBiotech is looking for 2013's fiercest women in biotech. Submit nominations here. | Follow @CarlyHFierce

> Analyst to Merck: Get to work chopping costs, preferably $1B-plus. Story

> Shire said to enlist help fighting off unwanted takeover. More

Pharma Manufacturing News

@EricPFierce: WSJ: Eisai sues DEA to get it to move on epilepsy drug Fycompa, which FDA approved in October. FiercePharma story | Follow @EricPFierce

> FDA program would allow inspectors to focus on trouble spots. More

> Ben Venue trimming manufacturing, jobs at troubled plant. Story

> Zydus Cadila injects $160M into injectables. Report

> Coup de grâce for Boehringer Ingelheim Virginia plant. More

> Ukraine sentences drug counterfeiter to 4 years. Item

Biotech Research News

@EmilyMFierce: The latest at Nerve cell death reversed in Parkinson's cells. Article | Follow @EmilyMFierce

> Industry-academic partnerships could help propel metabolic disease research. Editor's corner

> Diabetes progression slowed in mice. Story

> Inovio vaccine kills malaria, boosts immune response in animals. More

> Pluristem's stem cell therapy improves tendon injuries in rats. Item

> Seattle BioMed wins $16M NIH grant for TB research. Article